177 related articles for article (PubMed ID: 22766222)
21. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
[TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.
Schlenk RF; Döhner K; Mack S; Stoppel M; Király F; Götze K; Hartmann F; Horst HA; Koller E; Petzer A; Grimminger W; Kobbe G; Glasmacher A; Salwender H; Kirchen H; Haase D; Kremers S; Matzdorff A; Benner A; Döhner H
J Clin Oncol; 2010 Oct; 28(30):4642-8. PubMed ID: 20805454
[TBL] [Abstract][Full Text] [Related]
23. Late effects after hematopoietic stem cell transplantation--critical issues.
Tichelli A; Rovó A; Socié G
Curr Probl Dermatol; 2012; 43():132-49. PubMed ID: 22377926
[TBL] [Abstract][Full Text] [Related]
24. Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning.
Ganti AK; Lee SJ; Vose JM; Devetten MP; Bociek RG; Armitage JO; Bierman PJ; Maness LJ; Reed EC; Loberiza FR
J Clin Oncol; 2007 Dec; 25(35):5643-8. PubMed ID: 18065735
[TBL] [Abstract][Full Text] [Related]
25. Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant.
Danaher EH; Ferrans C; Verlen E; Ravandi F; van Besien K; Gelms J; Dieterle N
Oncol Nurs Forum; 2006 May; 33(3):614-24. PubMed ID: 16676017
[TBL] [Abstract][Full Text] [Related]
26. Introduction of the oncological pediatric risk of mortality score (O-PRISM) for ICU support following stem cell transplantation in children.
Schneider DT; Lemburg P; Sprock I; Heying R; Göbel U; Nürnberger W
Bone Marrow Transplant; 2000 May; 25(10):1079-86. PubMed ID: 10828869
[TBL] [Abstract][Full Text] [Related]
27. Disturbances in dental development and craniofacial growth in children treated with hematopoietic stem cell transplantation.
Vesterbacka M; Ringdén O; Remberger M; Huggare J; Dahllöf G
Orthod Craniofac Res; 2012 Feb; 15(1):21-9. PubMed ID: 22264324
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
29. High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan.
Chen MH; Chang PM; Li WY; Hsiao LT; Hong YC; Liu CY; Gau JP; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Bone Marrow Transplant; 2011 Apr; 46(4):567-72. PubMed ID: 20622906
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation.
Kanda J; Mizumoto C; Kawabata H; Ichinohe T; Tsuchida H; Tomosugi N; Matsuo K; Yamashita K; Kondo T; Ishikawa T; Uchiyama T
Biol Blood Marrow Transplant; 2009 Aug; 15(8):956-62. PubMed ID: 19589485
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
Yu ZP; Ding JH; Chen BA; Wu F; Gao C; Sun YY; Chen J; Zhao G; Wang J; Li YF; Ding BH; Qian J
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):283-6. PubMed ID: 21575500
[TBL] [Abstract][Full Text] [Related]
32. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
Espigado I; Ríos E; Marín-Niebla A; Carmona M; Parody R; Pérez-Hurtado JM; Márquez FJ; Urbano-Ispizua A
Transplant Proc; 2008 Nov; 40(9):3104-5. PubMed ID: 19010208
[TBL] [Abstract][Full Text] [Related]
33. Progressive declines in neurocognitive function among survivors of hematopoietic stem cell transplantation for pediatric hematologic malignancies.
Shah AJ; Epport K; Azen C; Killen R; Wilson K; De Clerck D; Crooks G; Kapoor N; Kohn DB; Parkman R; Weinberg KI
J Pediatr Hematol Oncol; 2008 Jun; 30(6):411-8. PubMed ID: 18525456
[TBL] [Abstract][Full Text] [Related]
34. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Uderzo C; Bonanomi S; Busca A; Renoldi M; Ferrari P; Iacobelli M; Morreale G; Lanino E; Annaloro C; Volpe AD; Alessandrino P; Longoni D; Locatelli F; Sangalli H; Rovelli A
Transplantation; 2006 Sep; 82(5):638-44. PubMed ID: 16969286
[TBL] [Abstract][Full Text] [Related]
35. Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.
Bevans MF; Mitchell SA; Barrett JA; Bishop MR; Childs R; Fowler D; Krumlauf M; Prince P; Shelburne N; Wehrlen L; Yang L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):387-95. PubMed ID: 24355521
[TBL] [Abstract][Full Text] [Related]
36. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
37. Patients' perception of health-related quality of life during the first year after autologous and allogeneic stem cell transplantation.
Andersson I; Ahlberg K; Stockelberg D; Persson LO
Eur J Cancer Care (Engl); 2011 May; 20(3):368-79. PubMed ID: 20345452
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation.
Deschler B; Binek K; Ihorst G; Marks R; Wäsch R; Bertz H; Finke J
Biol Blood Marrow Transplant; 2010 Jul; 16(7):967-75. PubMed ID: 20144720
[TBL] [Abstract][Full Text] [Related]
39. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.
Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation.
Worel N; Biener D; Kalhs P; Mitterbauer M; Keil F; Schulenburg A; Höcker P; Dieckmann K; Fischer G; Rosenmayr A; Linkesch W; Hinterberger W; Lechner K; Greinix HT
Bone Marrow Transplant; 2002 Nov; 30(9):619-26. PubMed ID: 12407437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
